Genentech, AbbVie Gain FDA Approval for Venclexta

The FDA has given the green light to the chronic lymphocytic leukemia treatment Venclexta, which will be marketed by AbbVie and Roche’s Genentech unit.

Co-developed by AbbVie and Roche, the Bcl-2 selective inhibitor is approved for patients with 17p deletion that is detected by an FDA-cleared diagnostic.